Related Experiment Video

Updated: Feb 4, 2026

Orthotopic Mouse Model of Colorectal Cancer
08:43

Orthotopic Mouse Model of Colorectal Cancer

Published on: December 4, 2007

47.2K

DDR1 inhibition as a new therapeutic strategy for colorectal cancer

Audrey Sirvent1, Marie Lafitte1, Serge Roche1

  • 1Centre de Recherche en Biologie cellulaire de Montpellier (CRBM), Univ Montpellier, CNRS 1919 Route de Mende, 34293 Montpellier, France.

Molecular & Cellular Oncology
|September 26, 2018
PubMed

Insights

Nilotinib, a leukemia drug, shows promise for treating metastatic colorectal cancer (mCRC). It inhibits cancer cell invasion by targeting the DDR1 receptor, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic colorectal cancer (mCRC) presents significant clinical management challenges.
  • Current treatment strategies for mCRC are limited in efficacy.
  • Understanding the molecular mechanisms of CRC metastasis is crucial for developing novel therapies.

Purpose of the Study:

  • To investigate the potential of nilotinib, a tyrosine kinase inhibitor, as a treatment for mCRC.
  • To determine if nilotinib affects the invasive and metastatic properties of colorectal cancer cells.
  • To identify the molecular target of nilotinib in CRC cells responsible for inhibiting metastasis.

Main Methods:

  • Utilized cell-based assays to assess the invasive and metastatic potential of CRC cells.
  • Examined the effect of nilotinib on colorectal cancer cell lines.
  • Investigated the interaction of nilotinib with the Discoidin Domain Receptor tyrosine kinase 1 (DDR1).

Main Results:

  • Nilotinib significantly inhibited the invasive and metastatic properties of colorectal cancer cells.
  • The drug's efficacy was linked to the inhibition of the kinase activity of DDR1.
  • DDR1 was identified as a key molecular target for nilotinib in the context of CRC metastasis.

Conclusions:

  • Nilotinib demonstrates potential as a novel therapeutic agent for managing mCRC.
  • Targeting DDR1 kinase activity with nilotinib offers a promising strategy to combat CRC metastasis.
  • Further clinical investigation of nilotinib for mCRC is warranted.
Keywords:
DDR1 tyrosine kinase receptorcollagencolorectal cancerinvasionmetastasisnilotinibtargeted therapy

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

7.1K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.5K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Therapeutic Communication01:30

Therapeutic Communication

Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.2K
Persuasion Strategies01:52

Persuasion Strategies

Researchers have tested many persuasion strategies, including the foot-in-the door and the door-in-the-face techniques, in a variety of contexts. Ultimately, the principles are effective in selling products and changing people’s attitude, ideas, and behaviors (Cialdini & Goldstein, 2004).
43.5K